Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations

Phase 2OpamtistomigPositive

AI Analysis

Summary

Leads Biolabs' pivotal Phase IIb study of Opamtistomig (LBL-024) in advanced EP-NEC has been selected as a late-breaking abstract for presentation at ESMO 2026, along with three additional studies selected for poster presentations.

Clinical Trial Data

Phase

Phase IIb

Importance:5/10

Sentiment:

0.60

Phase IIbESMO 2026Late-Breaking AbstractAdvanced EP-NECclinical trial

Read the original article

Published by GlobeNewswire Clinical Studies on September 21, 2026 2:46 PM

Read Original